- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 186 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 188 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 188 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 195 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 246 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- November 2024
- 170 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- November 2024
- 160 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- October 2024
- 130 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- August 2024
- 220 Pages
Global
From €5656EUR$5,950USD£4,752GBP

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness.
Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD.
Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more